EUVIMEDEUVIMED entdecken
Crossref

Isolated morular squamous metaplasia in endometrial biopsies and curettings: is there a role for repeated sampling?

Valentina Zanfagnin iD, Lawrence Hsu Lin iD, Kyle M Devins iD, Esther Oliva, Gulisa Turashvili iD

Histopathology · 2026-03 · 88 (4) · 889-897

DOI: 10.1111/his.70054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, online erschienen am 26.11.2025. Verfasst von Valentina Zanfagnin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Endometrium, Endometrial Hyperplasia, Carcinoma, Endometrioid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Endometrial atypical hyperplasia and low‐grade endometrioid carcinoma are often associated with morular squamous metaplasia. Limited evidence suggests that the finding of isolated morular squamous metaplasia without concomitant glandular neoplasia in biopsies is associated with a 6.5% risk of endometrial cancer in subsequent samples and warrants close follow‐up. However, its prognostic value has not been clearly determined. Methods and results The Massachusetts General Hospital pathology database was queried to identify endometrial samples with a diagnosis of ‘adenoacanthosis’, ‘morular metaplasia’, ‘squamous metaplasia’ or ‘morular squamous metaplasia’ between 2012 and 2024. Cases associated with endometrioid carcinoma, non‐atypical or atypical hyperplasia, atypical polypoid adenomyoma and gland crowding insufficient for diagnosis of atypical hyperplasia were excluded. Clinicopathologic data were collected. Outcomes were categorized as regression, persistence and progression to carcinoma. Of 32,800 endometrial samples reported during the study period, isolated morular squamous metaplasia was diagnosed in 57 (0.17%), including 42 (73.7%) biopsies and 15 (26.3%) curettings. The median patient age was 45 (21–70) years. Histologic follow‐up (at least one follow‐up sample) was available in 22 patients (median 30 months, 1–120) and included endometrial biopsy, curettage or hysterectomy. Of these 22 patients, a single follow‐up biopsy was performed in 9 (40.9%), a single curettage in 1 (4.5%), hysterectomy in 6 (27.3%), a single biopsy followed by hysterectomy in 2 (9.1%), multiple biopsies in 3 (13.6%) and a curettage followed by multiple biopsies and hysterectomy in 1 (4.5%). The median number of follow‐up samples was 2 (2–9) per patient. Histologically, the follow‐up samples were unremarkable (regression) in most patients (19/22, 86.4%), 2 (9.1%, aged 49 and 57 years) were diagnosed with grade 1 endometrioid carcinoma in subsequent hysterectomies, and 1 (4.5%, age 62) had persistent squamous morular metaplasia (follow‐up 69 months). In 15 patients with clinical follow‐up but no further pathology sampling, none had clinical symptoms at their last visit (100% clinical regression). Thus, the overall rate of endometrioid carcinoma was 5.4% (2/37).

Conclusions

Isolated squamous morular metaplasia without associated glandular neoplasia is a rare finding, reported only in 0.17% of endometrial samples. The risk of subsequent endometrioid neoplasia appears to be low (5.4%), although the possibility of undersampled atypical hyperplasia/endometrioid carcinoma cannot be completely ruled out without additional sampling. Persistent squamous morular metaplasia is relatively uncommon (4.5%) and may not lead to the subsequent diagnosis of endometrial cancer, questioning the utility of numerous repeat samplings in patients without progression after one repeat sample.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsEndometriumEndometrial HyperplasiaCarcinoma, EndometrioidHumansFemaleMetaplasiaMiddle AgedAgedAdultBiopsyYoung AdultCurettagePrecancerous Conditions

Stichwörter der Autor:innen

atypical hyperplasiaendometrioid carcinomaisolated squamous morular metaplasiamorular metaplasiasquamous metaplasia

Autor:innen und Institutionen

  • Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Valentina Zanfagnin, Lawrence Hsu Lin, Kyle M Devins, Gulisa Turashvili

Zitieren

APA

Zanfagnin, V., Hsu Lin, L., Devins, K. M., Oliva, E., & Turashvili, G. (2026). Isolated morular squamous metaplasia in endometrial biopsies and curettings: is there a role for repeated sampling?. Histopathology, 88(4), 889-897. https://doi.org/10.1111/his.70054

Vancouver

Zanfagnin V, Hsu Lin L, Devins KM, Oliva E, Turashvili G. Isolated morular squamous metaplasia in endometrial biopsies and curettings: is there a role for repeated sampling?. Histopathology. 2026;88(4):889-897. doi:10.1111/his.70054

BibTeX
@article{Zanfagnin2026,
  author = {Zanfagnin, Valentina and Hsu Lin, Lawrence and Devins, Kyle M and Oliva, Esther and Turashvili, Gulisa},
  title = {Isolated morular squamous metaplasia in endometrial biopsies and curettings: is there a role for repeated sampling?},
  journal = {Histopathology},
  year = {2026},
  volume = {88},
  number = {4},
  pages = {889--897},
  doi = {10.1111/his.70054}
}
Kostenlos starten →